TCT 2025 | INVEST-CTO: Effectiveness and Safety of a Planned Investment Procedure in High-Risk CTO PCI

The success rate of percutaneous coronary intervention (PCI) for chronic total occlusions (CTO) remains lower than for non-occlusive lesions, especially in complex CTOs. Furthermore, complications increase in prolonged and unsuccessful procedures, leading many CTO patients to be less frequently offered percutaneous revascularization.

When the initial attempt fails, a balloon dilation aimed at modifying the CTO is often performed, a strategy that has retrospectively shown to improve success rates in subsequent procedures.

The aim of the INVEST-CTO study was to determine whether, in patients with highly complex anatomical CTOs, a planned two-stage strategy—initial modification followed by a second procedure for complete recanalization—results in higher procedural success and improved safety.

The primary endpoint (PEP) was procedural success, defined as technical success without major adverse cardiac events (MACE: death, myocardial infarction, or clinically driven revascularization of the treated vessel). The secondary endpoint (SEP) was a 30-day safety composite.

Read also: TCT 2025 | INFINITY–SWEDEHEART: Long-Term Outcomes of the Bioadaptive Coronary Implant Versus Drug-Eluting Stent.

A total of 153 patients were analyzed, with a mean age of 66 years, predominantly male. The most common presentation was stable coronary artery disease. The mean J-CTO score was 4, indicating high complexity. The right coronary artery was most frequently involved (66%), followed by the left anterior descending (16%) and the circumflex (16%).

Regarding the PEP, the procedural success rate was 86.7% (95% CI 80.3–91.7; p < 0.05). For the SEP, the 30-day composite adverse event rate was 4.6%, suggesting a favorable safety profile.

Conclusion

A planned two-stage strategy for complex CTO intervention proved safe and effective. Initial modification of the CTO should be considered an early and rational approach in high-risk CTOs, with the potential to increase success rates and reduce complications.

Reference: Anja Øksnes, MD. TCT 2025.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Andrés Rodríguez
Dr. Andrés Rodríguez
Member of the Editorial Board of solaci.org

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

T-TEER: Beyond Traditional Pulmonary Hypertension Thresholds

Significant tricuspid regurgitation (TR) is associated with progressive functional deterioration, heart failure (HF) hospitalizations, and increased mortality. In recent years, transcatheter tricuspid edge-to-edge repair...

Is left atrial appendage closure safe in patients with reduced ejection fraction?

Patients with heart failure with reduced ejection fraction (HFrEF) were excluded from the major randomized trials evaluating percutaneous left atrial appendage closure (LAAC), and...

Left Atrial Appendage Closure in Spain: Sustained Growth and Favorable Real-World Outcomes

Oral anticoagulation remains the standard treatment for stroke prevention in patients with atrial fibrillation. However, many patients have a high bleeding risk or contraindications...